IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Pharma/fine chemicals roundup—21 October 2013

4:44 AM MDT | October 21, 2013 | Deepti Ramesh

AstraZeneca acquires ADC technology firm Spirogen AstraZeneca (London) says that its biologics R&D arm, MedImmune (Gaithersburg, MD), has acquired Spirogen (London), a privately held biotech company focused on antibody-drug conjugate (ADC) technology for use in oncology. MedImmune has also entered into a collaboration agreement with ADC Therapeutics (Lausanne, Switzerland) to jointly develop two of ADC Therapeutics’ ADC programs in preclinical development, AstraZeneca says. MedImmune will also make an equity investment in ADC Therapeutics, which has an...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


Comments (1) for Pharma/fine chemicals roundup—21 October 2013
Bitte lesen Sie das uber diese Firme aus Rumaenien und dann entscheiden Sie ob verdienen sie aufDeuschemarkt zukommen_
Posted by maria on Friday, October 25, 2013 @ 06:32 AM

contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa